Unravelling the Measles Paradox: a Disease Associated With Both Immune Suppression and Immune Activation

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The measles (MeV) paradox refers to an apparent contradiction: natural measles causes a transient but profound immune suppression putting patients at risk for opportunistic infections for years, while at the same time MeV infection induces robust immune activation leading to lifelong protection against measles. In this protocol, we test our hypothesis that natural measles causes immune amnesia by altering the composition of circulating immune memory cells. In comparison to the prior studies performed during the 2013 outbreak, we will specifically determine \[1\] to what extent pre-existing immunity is reduced, \[2\] for how long this functional immune suppression can be detected, and \[3\] to what extent MeV-specific immune cells expand. Recently, the WHO reported a 30-fold increase of the number of measles cases in the European Region in 2023 and the ECDC has published a threat assessment brief on increase of the number of cases and considerations for public health response. Combined with the reported drop in vaccination coverage, and several clusters of cases, we anticipate that we are at the verge of a new measles outbreak in the Netherlands

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

⁃ Cohort A

• 18 years or older

• No known history of measles or vaccination

• Decided to take MMR vaccination before the upcoming measles outbreak

⁃ Cohort B

• 18 years or older

• No known history of measles or vaccination (seronegative confirmed)

• Contracted measles during the upcoming outbreak

⁃ Cohort C

• 18 years or older

• No known history of measles or vaccination (seronegative confirmed)

⁃ Cohort D

• 18 years or older

• Experienced measles during the 2013 outbreak

⁃ Cohort E

• 18 years or older

• Received second dose of measles vaccines ±10 years ago

Locations
Other Locations
Netherlands
Erasmus MC
RECRUITING
Rotterdam
Contact Information
Primary
Dr C.H. Geurts van Kessel
c.geurtsvankessel@erasmusmc.nl
+31643271384
Time Frame
Start Date: 2025-07-03
Estimated Completion Date: 2028-07-30
Participants
Target number of participants: 300
Treatments
Group A (receive measles vaccine in 2024)
Participant who never had measles vaccine and are recently vaccinated against measles before the upcoming outbreak.
Group B (not vaccinated, measles infection during upcoming outbreak)
Participants who never had measles vaccine and decline recent offer for measles vaccine and get infected with measles during the upcoming outbreak.
Group C (not vaccinated, no measles infection during upcoming outbreak)
Participants who never had measles vaccine and decline recent offer for measles vaccine and remain free from measles infection.
Group D (not vaccinated, historical infection)
Participants who never had measles vaccine and had a history of measles infection.
Group E (historically vaccinated)
Participants who have received measles vaccine about 10 years ago.
Related Therapeutic Areas
Sponsors
Leads: Erasmus Medical Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials